Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Acquisition of Performance Share Units
SEC Form 4 Filing
Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of performance share units on December 23, 2024.
Summary
- On December 23, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, reported the acquisition of performance share units.
- These units are derivative securities that convert into common stock upon vesting.
- The reported transactions involve the acquisition of 14,000 and 38,640 performance share units, respectively.
- The performance share units were awarded on February 23, 2023, and February 22, 2024, and vested upon achievement of individual performance objectives.
- The objectives were established on June 12, 2023, and modified on December 12, 2024, for the first award, and established on June 24, 2024, for the second award.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of performance share units by the CEO can be seen as a slightly positive indicator.
Positives
- The CEO's acquisition of performance share units could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies.
Stakeholder Impact
- The acquisition of performance share units by the CEO could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Reporting Person was awarded Performance Share Units |
| June 12, 2023 | Objectives were established for Performance Share Units |
| February 22, 2024 | Reporting Person was awarded Performance Share Units |
| June 24, 2024 | Objectives were established for Performance Share Units |
| December 12, 2024 | Objectives were modified for Performance Share Units |
| December 23, 2024 | Transaction Date for acquisition of Performance Share Units |
| December 24, 2024 | Date of signature for the SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.